A Randomized, Phase II, Multicenter, Open Label, Study Evaluating Sirolimus and Prednisone in Patients With Refined Minnesota Standard Risk, Ann Arbor 1/2 Confirmed Acute Graft-Versus-Host Disease (BMT CTN 1501)
Latest Information Update: 02 Nov 2021
At a glance
- Drugs Sirolimus (Primary) ; Prednisone
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 19 Dec 2019 Status changed from active, no longer recruiting to completed.
- 18 Nov 2019 Results published in the Blood
- 19 Mar 2018 Planned End Date changed from 1 Oct 2020 to 1 Feb 2020.